In particular, muscle-skeletal receptor tyrosine-protein kinase (MUSK) levels were significantly decreased in converter samples relative to those of non-converters (Fig. 3E), and predicted conversion in this cohort with 100% specificity suggesting that this protein could be used in combination with OCGB to better predict the risk of a second clinical attack in CIS patients. The gene discussed is MUSK; the disease is in situ carcinoma.